ADMA Biologics (NASDAQ:ADMA) Shares Down 5.9% – What’s Next?

ADMA Biologics, Inc. (NASDAQ:ADMA) shares traded down 5.9% on Friday . The company traded as low as $19.86 and last traded at $19.94. 2,564,002 shares traded hands during trading, a decline of 31% from the average session volume of 3,741,586 shares. The stock had previously closed at $21.20.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on ADMA. Raymond James raised their target price on shares of ADMA Biologics from $25.00 to $32.00 and gave the stock a “strong-buy” rating in a research note on Thursday. Cantor Fitzgerald restated an “overweight” rating and set a $25.00 price objective on shares of ADMA Biologics in a research report on Tuesday, March 4th. Finally, StockNews.com downgraded shares of ADMA Biologics from a “hold” rating to a “sell” rating in a research note on Friday. One investment analyst has rated the stock with a sell rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, ADMA Biologics currently has an average rating of “Moderate Buy” and a consensus target price of $24.25.

ADMA Biologics Price Performance

The stock has a 50 day moving average price of $20.23 and a two-hundred day moving average price of $18.74. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. The firm has a market capitalization of $4.75 billion, a price-to-earnings ratio of 71.39 and a beta of 0.57.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.16 by ($0.02). The business had revenue of $114.80 million during the quarter, compared to analyst estimates of $116.40 million. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. The business’s revenue was up 40.2% on a year-over-year basis. During the same quarter last year, the firm earned $0.08 EPS. As a group, analysts expect that ADMA Biologics, Inc. will post 0.51 EPS for the current year.

Institutional Trading of ADMA Biologics

Institutional investors have recently bought and sold shares of the business. GAMMA Investing LLC lifted its position in shares of ADMA Biologics by 106.6% during the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company’s stock worth $32,000 after buying an additional 967 shares during the last quarter. Mark Sheptoff Financial Planning LLC purchased a new stake in ADMA Biologics in the fourth quarter valued at $35,000. Skandinaviska Enskilda Banken AB publ acquired a new position in ADMA Biologics in the first quarter valued at $35,000. Vision Financial Markets LLC purchased a new position in shares of ADMA Biologics during the fourth quarter worth about $51,000. Finally, Tsfg LLC acquired a new stake in shares of ADMA Biologics during the first quarter worth about $51,000. 75.68% of the stock is owned by hedge funds and other institutional investors.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.